Purpose: To report a retrospective, consecutive, noncomparative case series of moderate and severe stage 3 retinopathy of prematurity (ROP) in zone I or posterior zone II treated by bilateral intravitreal injections of bevacizumab (Avastin; Genentech, Inc., South San Francisco, CA).
T he role of vascular endothelial growth factor (VEGF) in the pathogenesis of retinopathy of prematurity (ROP) has been described. 1 Destruction of the cellular elements that release VEGF in the peripheral retina and adjacent to the extraretinal fibrovascular proliferation (both anterior and posterior) has proven to be effective. Less destructive therapies (laser therapy rather than cryotherapy) given earlier (rather than later) in the acute phase of ROP 2 with emphasis on a careful screening process that identifies ROP at the appropriate time for therapeutic intervention 3 are currently recommended. However, there is some controversy concerning this appropriate time with disagreement on identification of plus disease 4 and the thought that many surgeries performed are unnecessary. [5] [6] [7] [8] In contrast, it is well established that Neither author has any proprietary interest in any product mentioned in this report.
Reprint requests: Helen A. Mintz-Hittner, MD, University of Texas Professional Building, 6410 Fannin, Suite 920, Houston, TX 77030; e-mail: Helen.A.Mintz-Hittner@uth.tmc.edu zone I cases often have bad outcomes despite appropriate screening and timing of intervention (especially aggressive posterior ROP [AP-ROP]). 9 -14 With the development of anti-VEGF drugs for use by intravenous injection as adjunctive therapy for metastatic colorectal cancer (US Food & Drug Administration approved for bevacizumab in February 2004) and for metastatic lung cancer (US Food & Drug Administration approved for bevacizumab in October 2006) and their recent use by intravitreal injection for ocular diseases caused by neovascularization especially wet age-related macular degeneration (US Food & Drug Administration approved for ranibizumab in June 2006), the use of anti-VEGF drugs for treatment of ROP is now plausible. Obviously, there is considerable concern regarding the choice of drug, its dosage, the timing of injections, the possible need for multiple injections, the reality that local complications of ocular trauma or endophthalmitis may occur, and, most importantly, the possibility that both acute and long-term systemic complications may be caused by anti-VEGF therapy.
In 2007, there were three articles reported regarding the use of bevacizumab for treatment of AP-ROP. In all three reports, 0.75 mg (0.03 mL) was used as the intravitreal dose. In one report, a single AP-ROP case was treated with combination intravitreal injection of bevacizumab and indirect diode laser. 15 A second article described three cases of bilateral AP-ROP. Two infants were treated with unilateral intravitreal injections alone in the worse eye and laser therapy alone in the better eye. The third infant had laser therapy performed bilaterally, and a unilateral intravitreal injection was given in the worse eye with continued disease progression. 16 In the third report, bilateral intravitreal injections of bevacizumab were administered 2 weeks to 3 weeks after AP-ROP treated by 3,000 spots of near-confluent diode laser resulted in anterior segment ischemia with hypotony. 17 All three reports claimed success with no complications systemically. However, in the case of bilateral anterior segment ischemia, bilateral iris atrophy and lamellar cataracts developed (perhaps related to the extensive laser therapy rather than to intravitreal injection of bevacizumab). Results of two other studies utilizing unilateral or bilateral bevacizumab injections in infants with varying extents of ROP have been reported as abstracts; however, except to report safety and efficacy, these details have not been reported in articles.
We describe a retrospective, consecutive, noncomparative case series of 11 patients with moderate and severe stage 3 (vision-threatening) ROP in zone I or posterior zone II who were treated by a single injection of bevacizumab into each eye. Laser therapy was not given to any infant in this case series. There are many potential benefits of a less destructive therapy that can be done without (re)intubation of a fragile premature infant. These potential benefits include preventing the multiple complications of laser therapy itself, eliminating visual field loss due to retinal atrophy (especially in zone I cases), decreasing myopia related to scleral weakening, and reducing strabismus without amblyopia (associated with a smaller area of overlapping field) or with amblyopia (due to asymmetric macular disease or deprivation from unequal media opacities related to an unequal inflammatory response to laser, to unilateral cataract after laser, or to unilateral anterior segment or intravitreal hemorrhage).
An additional benefit of anti-VEGF therapy over laser therapy is the fact that anti-VEGF therapy immediately halts the continued advance of the neovascularization of ROP due to VEGF already present in the vitreous. Of course, laser decreases the production of additional VEGF but has no effect on VEGF already present in the vitreous. Anti-VEGF therapy may be administered to infants too sick to undergo general anesthesia. Further, infants with pupils too rigid to be fully dilated or with media too opaque for adequate visualization for laser therapy may still be treated safely by intravitreal injections of anti-VEGF agents rather than by blind external application of cryotherapy or phototherapy.
Methods
Zone I was defined according to the International Classification of Retinopathy of Prematurity Revisited 18 as a circle whose radius is two times the distance between the center of the optic disc and the center of the macula. Posterior zone II was defined as a circle whose radius is three times the distance between the center of the optic disc and the center of the macula. The International Classification of Retinopathy of Prematurity Revisited also subdivided the severity of stage 3 into mild, moderate, or severe depending on the extent of extraretinal fibrovascular tissue infiltrating the vitreous. Only patients with bilateral moderate or severe stage 3 ROP were considered candidates for this study. No infant with a congenital systemic or ocular anomaly was included in this series. Two infants were referred with preexisting severe stage 3 ROP. One infant presented with AP-ROP. These three infants were treated immediately. Screening was done by current criteria. 3 However, when mild stage 3 ROP was identified in eight infants with debatable plus disease, they were observed until they developed moderate stage 3 ROP with the presence of definite plus disease. This approach was intended to minimize the number of treated cases that might have otherwise spontaneously regressed. Thus, the timing of the injections was later than recommended by the Early Treatment of Retinopathy of Prematurity Study 2 but earlier than recommended by the Cryotherapy for Retinopathy of Prematurity Study 19 with the presence of definite plus disease.
No infant was treated before definite plus disease was present. 18 All infants were followed closely by indirect ophthalmoscopy for recurrence; however, no recurrences developed. All cases were photographed by the RetCam Imaging System (Clarity Medical Systems, Pleasanton, CA) immediately before and 1 week, 1 month, and 2 months after the bilateral single injections. Each infant underwent photography at the time of the most recent examination to demonstrate the extent of continued vascular growth anteriorly from the original location of moderate or severe stage 3 ROP.
The injections were done utilizing a continuous cardiorespiratory monitor with infants not intubated receiving oral medications for conscious sedation and local proparacaine hydrochloride (0.5%) ophthalmic solution and infants still intubated receiving intravenous general anesthetic agents. Bevacizumab was obtained from a compounding pharmacy that purchased commercially available Avastin (Genentech, Inc., South San Francisco, CA). The medication was supplied in sterile unit doses of 0.625 mg (0.025 mL) in single-use 0.3-mL syringes with a 0.5-in 30-gauge needle attached. These syringes were prepared in compliance with USP Chapter 797 Guidelines and were stored in light-resistant bags in a refrigerator at 4°C until the injections were given.
Sterile gloves, speculum, and forceps were utilized while administering the injections. A speculum for premature infants was placed between the lids. A drop of povidone-iodine (5%) ophthalmic solution was placed into the conjunctival sac for 1 minute with the excess removed by a sterile cotton tip applicator from the temporal lid margin. The eye was stabilized with a toothed forceps while the dose of bevacizumab (0.025 mL [0.625 mg]) was injected (nasally, by personal preference) behind the lens. The needle, aimed posteriorly (toward the optic nerve), entered the sclera through the conjunctiva Ϸ1.5 mm behind the limbus and was advanced approximately two thirds of the length of the needle (not to the hub), and the syringe was emptied completely into the central vitreous.
(Whether the injection was through the undeveloped pars plana or through the most anterior, avascular, undifferentiated peripheral retina, care was taken to avoid the unusually large lens of the premature infant.) After the injection, povidone-iodine was again placed into the conjunctival sac for 1 minute with the excess removed by a sterile cotton tip applicator from the temporal lid margin. The speculum was then removed from between the lids. The same procedure was repeated for the other eye. An ophthalmic antibiotic drop (gatifloxacin [0.35%] or moxifloxacin [0.5%]) ophthalmic solution) was prescribed for both eyes to begin immediately and be continued every 6 hours for 7 days after the bilateral intravitreal injections. Indirect ophthalmoscopy was utilized to look for any injury to the lens, to determine the presence of adequate blood flow through the central retinal artery, and to identify any retinal tears or vitreous hemorrhage immediately after the injection. With the lid closed, tactile pressure was determined. Indirect oph- thalmoscopy was performed also on the following day to specifically look for any sign of vitreous infection. None of the above-mentioned complications was encountered in the 11 patients.
Results
This retrospective, consecutive, noncomparative case series of 11 patients (Table 1) 
Six of the infants had confirmed sepsis. Six patients required patent ductus arteriosus ligation, and seven had intraventricular hemorrhage (grade II, 2; grade III, 1; grade IV, 4) before receiving intravitreal injections of bevacizumab. The mean birth weight for the 7 infants with ROP in posterior zone II was 785.7 g (mean gestational age, 24.9 weeks) compared with 567.5 g (mean gestational age, 23.3 weeks) for the 4 infants with ROP in zone I. The seven infants with ROP in posterior zone II generally had fewer and less severe systemic complications.
Eight of the infants were inpatients when they received intravitreal injections of bevacizumab. The retrospective review of these eight consecutive cases had institutional review board approval. In addition to these eight inpatients, three infants (Cases 6, 9, and 11 [all with moderate stage 3 ROP in posterior zone II]) were referred during the same period for "routine outpatient ROP screening" soon after discharge from community hospitals with level 3 neonatal intensive care units but no inpatient ROP screeners. The parents of these infants were offered off-label treatment with intravitreal injections of bevacizumab (utilizing chloral hydrate by mouth and proparacaine hydrochloride ophthalmic drops in the conjunctiva) in the office to prevent readmission to the hospital with the necessary reintubation for general anesthesia and laser therapy. Informed consent was obtained from the parents of all 11 patients.
All 22 eyes were treated successfully, with only 1 injection required to induce regression of acute ROP and continued vascularization of the peripheral retina to the extent that astrocytes (called "spindle cells") had migrated before preterm birth. 20 There was a beneficial role of bevacizumab in rapidly reducing engorged iris and anterior tunica vasculosa lentis vessels to permit dilation of the pupils. In Case 2, laser surgery was impossible before treatment with intravitreal injection of bevacizumab (Fig. 1A) and was unnecessary after anti-VEGF therapy (Fig. 1B) .
AP-ROP was successfully treated by bevacizumab. In Case 1, AP-ROP in zone I was present before treatment (Fig. 2A) ; after treatment, there was disappearance of the retinopathy and continued anterior retinal vascularization (Fig. 2B) .
Case 3 revealed the effectiveness of intravitreal injection of bevacizumab for treatment of severe stage 3 ROP in zone I. Extraretinal fibrovascular proliferation present both superior and inferior to the typical indentation toward the macula (Fig. 3A) disappeared, and retinal vessels continued their anterior growth (Fig. 3B) . Thick extraretinal fibrovascular proliferation on the nasal side with a large hemorrhage on the retinal surface (Fig. 4A) resolved with little evidence of the original retinopathy and continuation of anterior retinal vascularization (Fig. 4B) .
Moderate stage 3 ROP in posterior zone II with plus disease responded well to bevacizumab treatment. Preoperatively, thick extraretinal fibrovascular proliferation with plus disease occurred in Case 8 (Fig. 5A) . Postoperatively, there was a thin fibrous remnant of the previous proliferation, but retinal vessels advanced anteriorly beyond the fibrous remnant (Fig. 5B) .
High magnification of the temporal retina in Case 9 (moderate stage 3 ROP in posterior zone II) (Fig. 6A) emphasized the virtually complete disappearance of extraretinal fibrovascular proliferation with continued anterior growth of vessels into the previously avascular retina (Fig. 6B) .
Ophthalmic examinations revealed central and steady fixation without strabismus (if severe central nervous system injury was not present), pupils that were round and could be fully dilated, clear corneas and lenses, and minimal or no myopia or anisometropia. No trauma to the ocular structures was identified, and no endophthalmitis occurred.
Most infants had moderate to severe central nervous system problems diagnosed before treatment with intravitreal injections of bevacizumab; thus, neurologic effects in these infants would be difficult to ascertain. However, no systemic thrombotic events, hypertension, or gastrointestinal hemorrhages were recorded after the intravitreal injections of bevacizumab.
Discussion
The choice of bevacizumab was deliberate to try to minimize the possibility of systemic complications. The molecular weight of bevacizumab is 149 kd, that of VEGF-trap (investigational) is 110 kd, and that of ranibizumab (Lucentis; Genentech, Inc.) is 48 kd. It is especially undesirable to inject a small molecule that might easily penetrate into the undifferentiated peripheral retina and cause local damage. In addition, a small molecule could potentially traverse the retinal barrier completely and escape into the circulation in amounts more likely to cause systemic complications. Only 1:1,000 of the bevacizumab level in the treated eye has been shown (in rabbits) to be present in the nontreated eye or in the blood. 21 In adults, the intravitreal half-life of bevacizumab is 5.6 days, that of VEGF-trap is 4.4 days, and that of ranibizumab is 3.2 days. Injection of substances into the preterm vitreous, which is very viscous compared with the more liquefied aging vitreous, likely increases this half-life considerably. The choice to refrain from laser therapy also was deliberate to try to minimize the possibility of systemic complications. Laser therapy to destroy the natural barrier of the full thickness retina with an intact Bruch membrane would likely increase the exit of bevacizumab via the larger choroidal vessels into the blood. This case series deliberately included patients with ROP in posterior zone II to have a better chance to identify central nervous system complications in those infants without intraventricular hemorrhage.
Similarly, the decision to give bilateral intravitreal injections was deliberate to avoid creating a case series of amblyopic eyes due to the unilateral visual deprivation caused by the inflammatory response, cataract, hemorrhage, or other complications after laser therapy.
Another favorable circumstance is that vascularization of the preterm peripheral retina is a finite process. Vascularization only progresses in the retina to the extent of the astrocytes (called "spindle cells") present in the preterm retina at the time of birth. Vascularization does not necessarily extend to the ora serrata especially in infants with a low gestational age at birth. 20 Once inner retinal vascularization proceeds in an orderly fashion to its embryonic destination determined by gestational age (without the formation of tractional membranes), the disease process does not recur and should not cause late retinal detachments, which have been reported in the months and years after both cryotherapy and laser therapy. Intraocular injection of bevacizumab has a rapid and profound effect on flat neovascularization and plus disease, including venous dilation, arteriolar tortuosity, vitreous haze, iris vascular engorgement, and pupillary rigidity. All of these undergo marked diminution within 24 hours and virtually complete resolution within 48 hours. Elevated neovascularization, termed "extraretinal fibrovascular proliferation," also involutes but at a much slower rate, which may be a function of larger tissue volume. This neovascularization becomes gray within 1 week and then turns white, becomes less dense, and eventually separates from the retina. Months later, the extraretinal fibrovascular proliferation is often difficult to locate but may be seen as a white wisp or linear remnant floating in the vitreous. Therefore, whether the neovascularization is flat or elevated in zone I or posterior zone II, the response to anti-VEGF therapy is regression of abnormal vessels and the advancement of normal retinal vessels. However, the growth of normal retinal vessels after intravitreal injection of bevacizumab is often slower than the growth of normal retinal vessels. Thus, because vascularization does not necessarily always extend to the ora serrata if the infant is significantly premature and because vascularization may be slower than normal, the time to discontinue retinal examinations is less certain. In this small series, no recurrences were observed with a minimum of 3 months of follow-up after intravitreal injections of an anti-VEGF agent.
In this retrospective, consecutive case series, the mean follow-up was 48.5 weeks (Ϸ6 months; range, 3-20 months) after intravitreal injections of bevacizumab at a mean postnatal age of 11.0 weeks. Thus, the mean postnatal age at the last visit was 46.6 weeks (Ϸ11 months). These preliminary results are promising, without any early local or systemic complications. They are presented for further consideration. The uniform success of intravitreal injections of bevacizumab in this very limited series of 22 eyes with moderate and severe stage 3 ROP in zone I or posterior zone II warrants a prospective, randomized, controlled, multicenter clinical trial.
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